Physician profile
Peter Mathern
NPI 1316995699
$18,069.01
in general payments reported to CMS, 2019-2025
81 companies · $3,044 in 2025
The $3,044 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,354 · 2020: $461 · 2021: $137 · 2022: $6,319 · 2023: $2,777 · 2024: $2,977 · 2025: $3,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,639 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,638.54 |
| Education | $159.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $1,293.95 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Merck Sharp & Dohme LLC | $1,162.72 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Veracyte, INC. | $993.96 | 2022 | |
| Janssen Biotech, INC. | $961.29 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Lilly USA, LLC | $896.89 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Pfizer INC. | $879.39 | 2019-2025 | |
| Incyte Corporation | $728.39 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $701.18 | 2019-2025 | Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $701.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $696.63 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Genentech USA, INC. | $587.41 | 2019-2025 | Polivy, Lunsumio, Gavreto |
| Astellas Pharma US INC | $538.53 | 2019-2025 | Xospata, Vyloy, Padcev |
| Amgen INC. | $476.87 | 2019-2023 | Kyprolis, Blincyto, Xgeva |
| Celgene Corporation | $397.07 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Genzyme Corporation | $391.16 | 2019-2024 |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mathern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.